Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
Status:
RECRUITING
Trial end date:
2031-05-01
Target enrollment:
Participant gender:
Summary
The EPOCA study (Evaluation of a POlypill and Colchicine for risk reduction in patients with established Atherosclerotic cardiovascular disease) will be a randomized, superiority, parallel, 2x2 factorial, multicenter clinical trial which will include at least 7713 and up to a maximum of 10797 participants with established atherosclerotic cardiovascular disease.